In Brief
This article was originally published in The Tan Sheet
Executive Summary
Woodcock: FDA maintains NSURE focus; J&J rebrands to regain consumer trust; Symrise AG gains research loan; most allergy sufferers take two or more meds, Teva-funded survey finds; Mead Johnson’s Nutramigen LGG reduces milk allergies; more news In Brief.
You may also be interested in...
J&J OTC Business Returns To Double-Digit U.S. Growth In Q1
The domestic OTC/nutritionals business grew more than 14% in the first quarter on the strength of McNeil products returning to market and a severe cold and flu season. Johnson & Johnson’s consumer performance exceeded some market analyst estimates.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.